Trade-Ideas LLC identified Cerner ( CERN) as a post-market laggard candidate. In addition to specific proprietary factors, Trade-Ideas identified Cerner as such a stock due to the following factors:

  • CERN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $103.0 million.
  • CERN is down 6.1% today from today's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in CERN with the Ticky from Trade-Ideas. See the FREE profile for CERN NOW at Trade-Ideas

More details on CERN:

Cerner Corporation designs, develops, markets, installs, hosts, and supports healthcare information technology, healthcare devices, hardware, and content solutions for healthcare organizations and consumers in the United States and internationally. CERN has a PE ratio of 37. Currently there are 21 analysts that rate Cerner a buy, no analysts rate it a sell, and 2 rate it a hold.

The average volume for Cerner has been 2.1 million shares per day over the past 30 days. Cerner has a market cap of $18.8 billion and is part of the technology sector and computer software & services industry. The stock has a beta of 1.10 and a short float of 5.8% with 9.00 days to cover. Shares are down 8.8% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates Cerner as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, growth in earnings per share and increase in net income. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself.

Highlights from the ratings report include:
  • CERN's revenue growth has slightly outpaced the industry average of 26.3%. Since the same quarter one year prior, revenues rose by 34.2%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • CERN's debt-to-equity ratio is very low at 0.16 and is currently below that of the industry average, implying that there has been very successful management of debt levels. To add to this, CERN has a quick ratio of 1.81, which demonstrates the ability of the company to cover short-term liquidity needs.
  • The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Health Care Technology industry and the overall market, CERNER CORP's return on equity exceeds that of both the industry average and the S&P 500.
  • CERNER CORP has improved earnings per share by 13.5% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, CERNER CORP increased its bottom line by earning $1.50 versus $1.13 in the prior year. This year, the market expects an improvement in earnings ($2.07 versus $1.50).
  • The company, on the basis of net income growth from the same quarter one year ago, has significantly outperformed against the S&P 500 and exceeded that of the Health Care Technology industry average. The net income increased by 14.2% when compared to the same quarter one year prior, going from $129.00 million to $147.28 million.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.